Brought to you by 
GSK acquires sirtuin-targeting firm Sirtris for $720mm
16 May 2008
Executive Summary
GlaxoSmithKline will tender $720mm in cash to acquire public start-up Sirtris Pharmaceuticals (sirtuin modulation drug development).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com